Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE (ESPE 2018)

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Poster Presentations

Bone, Growth Plate & Mineral Metabolism P1

hrp0089p1-p025 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Intrauterine Growth Restriction, Antenatal Steroids, Gestational Age and Breast Feeding Influence Bone Health in Prepubertal Children Born Preterm

Iorgi Natascia Di , Calcagno Annalisa , Diana Paola , Notarnicola Sara , Allegri Anna Maria Elsa , Napoli Flavia , Cangemi Giuliana , Calevo Mariagrazia , Ramenghi Luca , Maghnie Mohamad

Objectives: To assess the long-term impact of prematurity on bone and body composition by using Dual-energy X-ray absorptiometry (DXA).Methods: DXA scans were performed in 100 preterm (PT) (n=42F, n=58M, mean weeks’gestation 31.5±2.6; range 26−36) and 51 born at term (BT) healthy infants (n=28F, n=23M). DXA measures of total body and lumbar spine mineral density (TB/L1-L4 BMD, g/cm2 and Z...

hrp0089p1-p026 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Duration of Breastfeeding and Bone Mineral Density in Childhood – A Prospective Study Among Preschool Children

Tint Mya Thway , Pang Wei Wei , Vasanwala Rashida Farhad , Padmapriya Natarajan , Ng Sharon , Soh Shu E , Chong Mary Fong-Fong , Shek Lynette Pei Chi , Gluckman Peter D , Chong Yap-Seng , Godfrey Keith M , Fortier Marielle V , Eriksson Johan G , Lee Yung Seng , Zhang Cuilin , Yap Fabian

Background: Bone growth and mineralization during childhood are now recognized as important for bone health in adulthood, leading to renewed interest in identifying modifiable factors that impact bone mineral density (BMD) in childhood. Emerging data suggest that duration of breastfeeding may affect BMD in later childhood and adult life. However, such data are sparse and inconsistent.Objectives: This study examined the relationship betwe...

hrp0089p1-p027 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Bone Health in Adolescents Born Small for Gestational Age (SGA)

Petraitiene Indre , Basevicius Algidas , Albertsson-Wikland Kerstin , Verkauskiene Rasa

Background: Subjects born small for gestational age (SGA) are at higher risk for metabolic, hormonal and reproductive problems later in life and about 2–10% of children born SGA do not catch-up in height. All these changes may influence bone mineral density (BMD).Aim: To evaluate hormonal profile and BMD in adolescents born SGA in comparison to their peers born appropriate for gestational age (AGA).Methods: 103 children were e...

hrp0089p1-p028 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Longitudinal Study of Bone Mass in Swedish Children Treated with Modified Ketogenic Diet

Svedlund Anna , Hallbook Tove , Magnusson Per , Dahlgren Jovanna , Swolin-Eide Diana

Purpose: Modified ketogenic diet (MKD) is one treatment option for intractable epilepsy and metabolic conditions such as glucose transporter type 1 deficiency syndrome (GLUT1-DS) and pyruvate dehydrogenase complex (PDC) deficiency. MKD is a less restrictive diet than the classical ketogenic diet (KD) and thus more tolerable. Childhood is an important period for bone acquisition. Some studies indicate a negative effect on bone mass during KD treatment, probably as a consequence...

hrp0089p1-p029 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Fracture Epidemiology for Children in Western Australia between 2005–2015: Do We Need to be Concerned about Bone Health?

Jenkins Mark , Nimphius Sophia , Hart Nicolas , Chivers Paola , Rantalainen Timo , Ruter Kristina , Borland Meredith , McIntyre Fleur , Stannage Katherine , Siafarikas Aris

Aim: Western Australia is a state with unique geography and population distribution having only a single tertiary paediatric hospital (Princess Margaret Hospital, PMH in Perth) managing the majority of children and adolescents with fractures in the Emergency Department (ED). Fracture incidence in 0–16 year olds is known to be high and varies between countries with boys having a 1.5 fold higher fracture incidence than girls. There are no specific data for Australia. The ai...

hrp0089p1-p030 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Bone Biochemistry in Children with Fractures Presenting with Suspected Non-accidental Injury

Forbes Owen , McNeilly Jane , McDevitt Helen , Houston James , Ahmed S. Faisal , Mason Avril

Introduction: Fractures have been recorded in up to one third of children who have suffered from physical abuse. The British Paediatric and Adolescent Bone Group (BPABG) position statement on vitamin D states that the level of 25 hydroxyvitamin D is not relevant to causation of fractures unless there is radiological or biochemical evidence of rickets. Clinicians are often asked in the court setting about the relevance of abnormal serum investigations in children who have fract...

hrp0089p1-p031 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Systematic Screening Using DXA Lateral Vertebral Morphometry is Associated with a High Prevalence of Vertebral Fractures in Duchenne Muscular Dystrophy: Results from ScOT-DMD Study

Joseph Shuko , Shepherd Sheila , Marco Marina Di , Dunne Jennifer , McMillan Martin , Horrocks Iain , Ahmed S Faisal , Wong Sze Choong

Background: The prevalence of vertebral fractures (VF) in Duchenne Muscular Dystrophy (DMD) is currently unknown as systematic spine imaging is rarely performed.Objective: To determine the prevalence of VF in DMD and factors associated with VF.Method: A prospective study utilising systematic screening with DXA vertebral fracture assessment (VFA) was performed in all 47 eligible boys. 6/47 were excluded due to spinal instrumentation...

hrp0089p1-p032 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Bone Mineral Density and Glycemic Control in Children and Adolescents with Type 1 Diabetes Mellitus

Fuusager Gitte , Christesen Henrik Thybo , Milandt Nikolaj , Schou Anders Jorgen

Background/aim: Osteoporosis is a known complication in adults with type 1 diabetes mellitus (T1DM), but whether the bones are affected in children and adolescents with T1DM remains controversial. The study aim was to evaluate bone mineral density (BMD) in children and adolescents with T1DM and identify risk factors associated to lower BMD.Method: In a single-center cohort of children and adolescents with T1DM, BMD was examined by dual-energy X-ray absor...

hrp0089p1-p033 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Comparison of Manual and Automated Bone Age Assessment in 1285 Children and Adolescents Aged 5 to 16 Years

Maratova Klara , Zemkova Daniela , Lebl Jan , Soucek Ondrej , Pruhova Stepanka , Kolouskova Stanislava , Snajderova Marta , Krasnicanova Hana , Sumnik Zdenek

Background: Skeletal maturation is the most reliable indicator of biological age in children and adolescents. The evaluation of hand and wrist X-Ray according to Tanner-Whitehouse (TW3) or Greulich-Pyle (GP) are the most commonly used methods for biological age assessment. Automated bone age assessment has recently become increasingly popular, however a large independent study comparing automated and manual evaluation of bone age is still missing. The aim of this study was to ...

hrp0089p1-p034 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Is Plasma C-Type Natriuretic Peptide Level Available for Typing and Diagnosis of Skeletal Dysplasia Cases?

Kizilcan Cetin Sirmen , Goksen Damla , Ozen Samim , Alper Hudaver , Isık Esra , Onay Huseyin , Darcan Sukran

Introduction: Skeletal dysplasia is a heterogeneous group of disease, leading to abnormal enchondral ossification and typing of the disease is quite complex. C-type natriuretic peptide (CNP), one of the members of the natriuretic peptide family, has been implicated to play a role in bone development. CNP levels were high in some types of the skeletal dysplasia.Objective: The aim of this study is to evaluate the possibility of using CNP, as a marker for s...

hrp0089p1-p035 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Long-term Outcomes of Osteogenesis Imperfecta in the Bisphosphonate Era

Feehan Andrew , Zacharin Margaret , Lim Angelina , Simm Peter

Background: Bisphosphonates have been used for treatment of bone fragility disorders for over 25 years to increase bone mineral density (BMD). Anecdotally, bisphosphonate-treated Osteogenesis Imperfecta (OI) has a different trajectory to the natural history of untreated OI, with minimal published evidence to support this clinical observation.Aims: To describe functional outcomes of a cohort of adults with OI, stratified according to severity and treated ...

hrp0089p1-p036 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Novel LRP5 Loss-of-function Mutation Causes Osteoporosis-pseudoglioma Syndrome

Braslavsky Debora , Scaglia Paula , Sanguineti Nora , Cassinelli Hamilton , Ruiz Schenstrom Olivia , Armando Romina , Arberas Claudia , Aza-Carmona Miriam , Nevado-Blanco Julian , Daniel Lapunzina-Badia Pablo , Heath Karen E , Rey Rodolfo , Bergada Ignacio

Background: Osteoporosis is a complex disorder, influenced by both environmental and genetic factors. Primary osteoporosis is a rare early onset disorder with high morbidity and mortality. Wnt signaling pathway has been shown to be involved in the regulation of bone remodeling.Case: Native Argentinean boy born from a consanguineous family with history of retinal detachment in the maternal line. Delivered at term, birth weight 2900 g (−0.95 SDS), bi...

hrp0089p1-p037 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Hypercalcaemia after Treatment with Denosumab in Children: Bisphosphonates as an Option for Therapy and/or Prevention?

Sydlik Carmen , Weissenbacher Claudia , Roeb Julia , Roland Durr Hans , Bechtold-Dalla Pozza Susanne , Schmidt Heinrich

Background: Pharmacologic options for treatment of osteolytic diseases especially in children are limited. Although not licensed for use, denosumab, a fully humanized antibody to RANKL, is used in children and shows good effects. Among others, one indication are giant cell tumors of the bone. Yet, there are reports of severe hypercalcemia after stop of denosumab, an adverse effect which is rarely seen in adults.Case reports: Four patients, aged 6, 13 and...

hrp0089p1-p038 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Disease Burden and Systemic Manifestations of HPP in Children Enrolled in the Global HPP Registry

Hogler Wolfgang , Langman Craig , Gomes Da Silva Hugo , Fang Shona , Linglart Agnes , Ozono Keiichi , Petryk Anna , Rockman-Greenberg Cheryl , Seefried Lothar , Kishnani Priya

Hypophosphatasia (HPP) is a rare, inherited, systemic disease caused by mutation(s) of the ALPL gene encoding tissue-nonspecific alkaline phosphatase (ALP), resulting in deficient ALP activity. Asfotase alfa is an enzyme replacement therapy approved for treatment of patients with pediatric-onset HPP. The global HPP Registry is an observational, prospective, multinational study (NCT02306720; EUPAS13514) established to collect real world clinical data from patients of a...

hrp0089p1-p039 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

3-epi-25 Serum 25-hydroxyvitamin D3 Concentrations in Chilean Children between 5 and 8 Years

Arancibia Monica , Seiltgens Cristian , Poggi Helena , Allende Fidel , Solari Sandra , Peredo Soledad , Trincado Claudia , Garcia Hernan , Moore Rosario , Dapremont Ivonne , Andrade Daniela , Sifaqui Sofia , Ossa Jt , Campino Carmen , Carvajal Cristian , Fardella Carlos , Baudrand Rene , Sanchez Ximena , Martinez-Aguayo Alejandro

Background: The C3 epimer of 25-hydroxi-vitamin D3 (Epi25OHD3) is present in the pediatric and adult population and varies according to age. If it measurement is clinically relevant and should be considered to classify Vitamin D status is still unknown.Objective: To measure 25OHD3, 25-hydroxy-Vitamin D2 (25OHD2) and Epi25OHD3 and to compare them with PTH and calcemia.Method: Subjects: Children between 5 and 8 years of age born very...